revlon eisb performance status update – february 2016
TRANSCRIPT
OBG PRESENTS:
EVO / Bioaugmentation for Treatment of Trichloroethene by Biobarrier and Source Injection ApproachChristine Fogas (OBG), Michael Kozar, P.G. (OBG), Bella Bakrania (OBG), and Eric Schleicher, P.G. (OBG)
Fourth International Symposium on Bioremediation and Sustainable Environmental TechnologiesMay 22-25, 2017, Miami, FL
Emulsified Vegetable Oil (EVO) and Bioaugmentation for Treatment of Trichloroethene(TCE) by “Biobarrier” and Source Injection Approach
2
Background
Implementation
Performance Monitoring
3
Background
Site Setting
4
5
6
Remedial Objectives
Remediate source / reduce CVOC mass flux
Enhance monitored natural attenuation (MNA) downgradient
Meet New Jersey Groundwater Quality Standards (GWQS) – TCE = 1 ppb; 1,1,1-TCA = 30 ppb
Key Considerations
Difficult urban setting
Treatment needed off-Site
Long-term solution / low maintenance
No aboveground equipment
7
▪ Showed TCE degradation, but accumulation of cDCE with electron donor only (MEAL)
▪ Showed complete dechlorination to ethene with Dhc addition (KB-1)
2001 Microcosm
▪ Conducted at a “hot-spot” in shallow source area
▪ 1st Injection = 65 lbs sodium lactate; 2nd Injection = 600 lbs sodium lactate
▪ Bioaugmentation with Dhc
2003 Field Pilot Study
▪ Used groundwater from off-site monitoring well where “biobarrier” was planned
▪ Tested new commercially available electron donors and buffers
2010 Microcosm
Enhanced In Situ Bioremediation (EISB) Proof of Concept
8
Cross Sectional View of Site
Biobarrier Segment “B”
Biobarrier Segment “A”
Source Area
9
Implementation
10
Overview / Chronology
11
• Initial (8) injection wells for EISB pilot test in source area installed June 2003
• Additional (25) injection wells installed January – March 2014
• Newman Zone® Standard Emulsified Vegetable Oil (EVO) was selected
• EVO injection completed over a period of 14 days (September 2014 – October 2014)
• Bioaugmentation conducted May 2015
• TSI-DC Dehalococcoides mccartyii Bioaugmentation Culture® supplied by Terra Systems, Inc.
• Groundwater (GW) sampling / monitoring events conducted:•Baseline (pre-EVO injection): May 2014
•Months 1 through 6: November 2014 – April 2015 (pre-bioaugmentation)
•Months 7 and beyond: August 2015 – April 2017 (post-bioaugmentation)
Injection Well
Install
EVO Injection
Bioaugment
Performance Monitoring
Injection WellInstallation
12
Off-site barrier well installations
9-ft high pile of plow snow covering two
planned drill locations
Compact Rotosonicdrill rig
EVO Injections
13
Newman Zone® product tote
Spill containment Gravity feed setup
Mixing tanks
Biobarrier injections
14
Actual vs. Target EVO Injected in Pounds
A total of 25,937 lbs of Newman Zone® Standard EVO at 10% concentration (31,438 gallons in solution) was injected in the EISB treatment zones over a period of 14 days
3,310
9,981
12,646
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
EVO
Inje
cte
d (
lbs)
SOURCE AREA BARRIER SEGMENT A BARRIER SEGMENT B
StoichiometricTarget LOW
(1,620)
Injection Porosity Target HIGH
(11,520)
Injection Porosity Target HIGH
(11,520)
Stoichiometric Target LOW
(3,266)
Injection Porosity Target HIGH
(12,370)
Stoichiometric Target LOW
(1,814)
Bioaugmentation
15
TSI-DC Bioaugmentation Culture® contains > 1 x 1011 cells/L of Dehalococcoides mccartyii
Self-performed bioaugmentation
Fouling Slowed Progress
Total of 336 liters of culture injected over a period of 7 days to achieve target concentration of 1 x 107 cells/L in groundwater
16
Performance Monitoring
EVO is fermented to release volatile fatty acids (VFAs), which act as a carbon source for Dhc and other microbes
17
EVO InjectionsComplete
Bioaugmentation
0
200
400
600
800
1000
1200
1400
0
100
200
300
400
500
600
Co
nce
ntr
atio
n (
mg
/L)
MW-8C: Volatile Fatty Acids (VFAs) (Source Area - Shallow GW Zone)
Lactic Acid
Acetic Acid
Propionic Acid
Formic Acid
Butyric Acid
Pyruvic Acid
EISB Monitoring Wells
18
19
Baseline TCE = 3,320 ppb
April 2017 TCE = 18.4 ppb
NJ GWQS for TCE = 1 ppb
EVO InjectionsComplete
Bioaugmentation
0
100
200
300
400
500
600
700
800
900
1,000
0
5
10
15
20
25
30
35
40
45
50
May
-14
Jun
-14
Jul-
14
Au
g-1
4
Sep
-14
Oct
-14
No
v-14
Dec
-14
Jan
-15
Feb
-15
Mar
-15
Ap
r-1
5
May
-15
Jun
-15
Jul-
15
Au
g-1
5
Sep
-15
Oct
-15
No
v-15
Dec
-15
Jan
-16
Feb
-16
Mar
-16
Ap
r-1
6
May
-16
Jun
-16
Jul-
16
Au
g-1
6
Sep
-16
Oct
-16
No
v-16
Dec
-16
Jan
-17
Feb
-17
Mar
-17
Ap
r-1
7
May
-17
Tota
l VFA
Co
nce
ntr
atio
n (
mg
/L)
VO
C C
on
cen
trat
ion
(µ
M)
MW-8C: EISB Source Area - Shallow Overburden Zone
PCE TCE cDCE VC Ethene + Ethane Total VFA's
20
Baseline TCE = 9,030 ppb
NJ GWQS for TCE = 1 ppb
April 2017 TCE = < 0.26 ppb
0
150
300
450
600
750
900
1,050
1,200
1,350
1,500
0
10
20
30
40
50
60
70
80
90
100
May
-14
Jun
-14
Jul-
14
Au
g-1
4
Sep
-14
Oct
-14
No
v-14
Dec
-14
Jan
-15
Feb
-15
Mar
-15
Ap
r-1
5
May
-15
Jun
-15
Jul-
15
Au
g-1
5
Sep
-15
Oct
-15
No
v-15
Dec
-15
Jan
-16
Feb
-16
Mar
-16
Ap
r-1
6
May
-16
Jun
-16
Jul-
16
Au
g-1
6
Sep
-16
Oct
-16
No
v-16
Dec
-16
Jan
-17
Feb
-17
Mar
-17
Ap
r-1
7
May
-17
Tota
l VFA
Co
nce
ntr
atio
n (
mg
/L)
VO
C C
on
cen
trat
ion
(µ
M)
MW-21: EISB Biobarrier - Deep Till Zone
PCE TCE cDCE VC Ethene + Ethane Total VFA's
21
Baseline TCE = 3,200 ppb
NJ GWQS for TCE = 1 ppb
April 2017 TCE = 2.1 ppb
EVO InjectionsComplete
Bioaugmentation
0
150
300
450
600
750
900
1,050
1,200
1,350
1,500
0
5
10
15
20
25
30
35
40
45
50
May
-14
Jun
-14
Jul-
14
Au
g-1
4
Sep
-14
Oct
-14
No
v-14
Dec
-14
Jan
-15
Feb
-15
Mar
-15
Ap
r-1
5
May
-15
Jun
-15
Jul-
15
Au
g-1
5
Sep
-15
Oct
-15
No
v-15
Dec
-15
Jan
-16
Feb
-16
Mar
-16
Ap
r-1
6
May
-16
Jun
-16
Jul-
16
Au
g-1
6
Sep
-16
Oct
-16
No
v-16
Dec
-16
Jan
-17
Feb
-17
Mar
-17
Ap
r-1
7
May
-17
Tota
l VFA
Co
nce
ntr
atio
n (
mg
/L)
VO
C C
on
cen
trat
ion
(µ
M)
MW-22: EISB Biobarrier - Deep Till Zone
PCE TCE cDCE VC Ethene + Ethane Total VFA's
22
TCE Concentrations (ppb)Historic Range* April 2017 Results
Source Area Monitoring Wells
MW-8 (shallow overburden)+ 110 – 3,300 < 0.26
MW-8B (shallow overburden) 54 - 760 5,270
MW-8C (shallow overburden) 130 - 6,100 18.4
MW-8D (shallow overburden) 42 - 17,000 < 0.26
MW-20 (intermediate till) 400 - 25,000 580
MW-18 (deep till) 130 - 340 148
Barrier Segment “B” Monitoring Well
MW-21 (deep till) 5,500 - 16,000 < 0.26
Barrier Segment “A” Monitoring Well
MW-22 (deep till) 580 - 9,000 2.1Notes:NJ GWQS for TCE = 1 ppb, cDCE = 70 ppbJ = estimated value* Excludes data from the EISB Pilot Test period (July 2003 – April 2004)+ cis-DCE concentrations shown for MW-8 (pilot test well)
23
1,1,1-TCA Concentrations (ppb)
Historic Range* April 2017 Results
Source Area Monitoring Wells
MW-8 (shallow overburden) 25 – 1,000 0.72 J
MW-8B (shallow overburden) < 1 - 24 714
MW-8C (shallow overburden) 1.2 - 190 0.78 J
MW-8D (shallow overburden) 2.5 - 710 < 0.22
MW-20 (intermediate till) 2.7 – 1,100 25.6
MW-18 (deep till) 0.7 – 5.9 0.42 J
Barrier Segment “B” Monitoring Well
MW-21 (deep till) < 13 - 100 < 0.22
Barrier Segment “A” Monitoring Well
MW-22 (deep till) 3.6 - 520 < 0.22
Notes:NJ GWQS for TCA = 1 ppbJ = estimated value*Excludes data from the EISB Pilot Test period (July 2003 – April 2004)
Sentinel Monitoring Well
24
25
Baseline TCE = 4,980 ppb
April 2017 TCE = 2,670 ppb
EVO InjectionsComplete
Bioaugmentation
5/1/20145/31/20146/30/20147/30/20148/29/20149/28/201410/28/201411/27/201412/27/20141/26/20152/25/20153/27/20154/26/20155/26/20156/25/20157/25/20158/24/20159/23/201510/23/201511/22/201512/22/20151/21/20162/20/20163/21/20164/20/20165/20/20166/19/20167/19/20168/18/20169/17/201610/17/201611/16/201612/16/20161/15/20172/14/20173/16/20174/15/2017
0
150
0
5
10
15
20
25
30
35
40
45
50
May
-14
May
-14
Jun
-14
Jul-
14
Au
g-1
4
Sep
-14
Oct
-14
No
v-14
Dec
-14
Jan
-15
Feb
-15
Mar
-15
Ap
r-1
5
May
-15
Jun
-15
Jul-
15
Au
g-1
5
Sep
-15
Oct
-15
No
v-15
Dec
-15
Jan
-16
Feb
-16
Mar
-16
Ap
r-1
6
May
-16
Jun
-16
Jul-
16
Au
g-1
6
Sep
-16
Oct
-16
No
v-16
Dec
-16
Jan
-17
Feb
-17
Mar
-17
Ap
r-1
7
Tota
l VFA
Co
nce
ntr
atio
n (
mg/
L)
VO
C C
on
cen
trat
ion
(µ
M)
MW-29: Sentinel A - Deep Till Zone
PCE TCE cDCE VC Ethene + Ethane Total VFA's
26
Post-Bioaugmentation
Sample collected for CENSUS-DNA analysis by Microbial Insights, Inc.
June 2015 Jan 2016 April 2017
MW-8C 1.90 x 109 N/A N/A
MW-20 2.13 x 107 N/A 3.46 x 10
6
MW-21 2.84 x 104
3.28 x 108
N/A
MW-22 7.58 x 108 N/A N/A
MW-29 4.80 x 103 N/A 1.90 x 10
3
MW-25BR N/A 2.20 x 108 N/A
Note:
Literature established 1 x 107 cells/L as a threshold for
generally useful rates of dechlorination (Lu et. Al., 2006)
CENSUS-DNA:Dehalococcoides (Dhc) Results (cells/L)
27
January 2012TCE = 850 ppb
April 2017 TCE = 41.7 ppb
EVOInjectionsComplete
Bioaugmentation
0
100
200
300
400
500
600
700
0
2
4
6
8
10
12
Jan
-12
Mar
-12
Jun
-12
Sep
-12
Dec
-12
Mar
-13
Jun
-13
Sep
-13
Dec
-13
Mar
-14
Jun
-14
Sep
-14
Dec
-14
Mar
-15
Jun
-15
Sep
-15
Dec
-15
Mar
-16
Jun
-16
Sep
-16
Dec
-16
Mar
-17
Jun
-17
Be
nze
ne
Co
nce
ntr
atio
n (
μg/
L)
VO
C C
on
cen
trat
ion
(µ
M)
MW-25BR: Sentinel B - Bedrock ZoneChlorinated Ethenes / Ethene + Ethane Concentrations
vs. Benzene Concentration over Time
Ethene + Ethane not measured
Baseline GW Sampling Event
(Pre- Full-Scale EISB)
Methane production is expected as a result of EISB
28
MW-8C MW-20 MW-21
Shallow/Source Int/Source Deep/Biobarrier
5/28/2014 8.4 2.9 230
11/4/2014 12 19 35
1/5/2015 280 20 3,300
6/10/2015 1,900 120 13,000
8/26/2015 3,300 440 27,000
1/14/2016 9,700 -- 26,000
9/26/2016 11,000 11,000 27,000
4/21/2017 15,000 6,300 17,000
Dissolved Methane in GW Results (ug/L)
Multigas meter used to check:
▪ Interior of Site building
▪ Basement spaces across street
▪ Nearby drainage inlets
▪ Shallow monitoring wells downgradient
No evidence of methane accumulation was found
Injection wells fitted with vented well caps to prevent methane gas buildup
Performance Monitoring Conclusions
29
EVO + bioaugmentation injections were successful in establishing conditions for EISB in the source area and biobarrier treatment zones
VFA depletion is not an immediate concern along the biobarriers and majority of source area
Dhc population is thriving in EISB treatment zones, as well as in the downgradient bedrock zone
Some of the VFAs are being utilized by methanogens, resulting in high levels of dissolved methane in groundwater
OBG PRESENTS:OBG | THERE’S A WAY